Insmed Inc [INSM] stock is trading at $166.95, up 1.00%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INSM shares have gain 4.08% over the last week, with a monthly amount glided 15.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on October 20, 2025, and set its price target to $171. On August 20, 2025, William Blair initiated with a Outperform rating. Morgan Stanley downgraded its rating to a Equal-Weight but stick to its price target of $126 on August 13, 2025. Jefferies initiated its recommendation with a Buy and recommended $105 as its price target on May 13, 2025. RBC Capital Mkts started tracking with a Outperform rating for this stock on February 25, 2025, and assigned it a price target of $100. In a note dated April 23, 2024, Truist initiated a Buy rating and provided a target price of $48 on this stock.
Insmed Inc [INSM] stock has fluctuated between $60.40 and $168.21 over the past year. Currently, Wall Street analysts expect the stock to reach $180.4 within the next 12 months. Insmed Inc [NASDAQ: INSM] shares were valued at $166.95 at the most recent close of the market. An investor can expect a potential return of 8.06% based on the average INSM price forecast.
Analyzing the INSM fundamentals
Insmed Inc [NASDAQ:INSM] reported sales of 398.11M for the trailing twelve months, which represents a growth of 18.90%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -2.38%, Pretax Profit Margin comes in at -2.59%, and Net Profit Margin reading is -2.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.95 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 164.59 points at the first support level, and at 162.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 168.55, and for the 2nd resistance point, it is at 170.14.
Ratios To Look Out For
For context, Insmed Inc’s Current Ratio is 6.68. Also, the Quick Ratio is 6.33, while the Cash Ratio stands at 4.12. Considering the valuation of this stock, the price to sales ratio is 88.64, the price to book ratio is 28.20.
Transactions by insiders
Recent insider trading involved Schaeffer Orlov S Nicole, Chief People Strategy Officer, that happened on Sep 12 ’25 when 76520.0 shares were sold. Director, SHAROKY MELVIN MD completed a deal on Sep 12 ’25 to sell 10000.0 shares. Meanwhile, Officer Schaeffer Orlov S Nicole bought 76520.0 shares on Sep 12 ’25.
